XWELL Inc

Aktienanalyse zu XWELL Inc (XWEL)

$0.589

+0.016 (+2.78%)Zum Schluss

Loading chart…
Hoch
0.589
Eröffnung
0.560
Volumengewichteter Durchschnittskurs
0.58
Volumen
16.99K
Marktkap.
7.36M
Tief
0.560
Umsatz
9.84K
EV/EBITDA, TTM
0.00

XWELL, Inc. is a global wellness company. The Company delivers restorative and health-focused services to travelers through its three operating segments: XpresSpa, XpresTest, and Naples Wax Center. XpresSpa operates spa service locations in major airports, offering massage, skincare, and travel products. The XpresTest segment provides aircraft wastewater and passenger nasal sampling through the Centers for Disease Control and Prevention's (CDC's) bio-surveillance program. The Naples Wax Center segment operates six locations with core products and service offerings from face and body waxing to a range of skincare and cosmetic products. Its health wellness beauty services include massage, waxing, facials, stretch, light emitting diode (LED) light therapy, meditation, manicures, pedicures, aromatherapy, anti-aging treatments, compression therapy, and massage chairs. Its subsidiaries include Naples Wax FRM LLC, Quantum Stream Inc., XpresSpa Holdings, LLC, XpresTest, Inc., and others.

www.xwell.com

KI-Analyse of XWELL Inc (XWEL)

Verkaufen

XWELL Inc is not a good buy right now due to its declining financial performance and negative market sentiment. The stock has a current price of $0.59, which is significantly lower than its 52-week high of $2.20, indicating a 73% drop from its peak. Additionally, the RSI is at 28.253, suggesting the stock is oversold, but this does not guarantee a rebound. The company reported a net loss of $22.4 million in Q2 2026, which raises concerns about its profitability. The stock has also seen a 14.72% drop over the last five days, reflecting ongoing negative sentiment.

Bewertungskennzahlen

Das aktuelle erwartete KGV von XWELL Inc (XWEL) beträgt 10.79, verglichen mit dem 5-Jahres-Durchschnitt von 0.23.

Erwartetes KGV

Stark überbewertet
5J-Durchschnitt P/E
0.23
Aktuelles P/E
10.79
Überbewertet
4.95
Unterbewertet
-4.48

Erwartetes EV/EBITDA

Fair bewertet
5J-Durchschnitt EV/EBITDA
-1.28
Aktuelles EV/EBITDA
0.00
Überbewertet
0.40
Unterbewertet
-2.96

Erwartetes KUV

Fair bewertet
5J-Durchschnitt P/S
0.66
Aktuelles P/S
0.00
Überbewertet
1.33
Unterbewertet
-0.01

Event-Zeitleiste

2026-07-07 (ET)

09:30:00

Xwell Divests XpresSpa and XpresTest for $13M

2026-04-01 (ET)

16:40:00

XWELL CEO Emphasizes Brand Relevance and Market Expansion

2026-02-03 (ET)

08:30:00

Xwell Partners with PieQ for Biosecurity Forecasting Platform

2026-01-08 (ET)

08:30:00

XWELL Expands Global Biosecurity Strategy, Appoints Former CDC Advisor as Senior Advisor

2025-12-18 (ET)

08:20:00

XWELL Opens New Location in New York's Pennsylvania Station

News

XWEL FAQ – beantwortet von Alphio AI

XWELL, Inc. is a global wellness company. The Company delivers restorative and health-focused services to travelers through its three operating segments: XpresSpa, XpresTest, and Naples Wax Center. XpresSpa operates spa service locations in major airports, offering massage, skincare, and travel products. The XpresTest segment provides aircraft wastewater and passenger nasal sampling through the Centers for Disease Control and Prevention's (CDC's) bio-surveillance program. The Naples Wax Center segment operates six locations with core products and service offerings from face and body waxing to a range of skincare and cosmetic products. Its health wellness beauty services include massage, waxing, facials, stretch, light emitting diode (LED) light therapy, meditation, manicures, pedicures, aromatherapy, anti-aging treatments, compression therapy, and massage chairs. Its subsidiaries include Naples Wax FRM LLC, Quantum Stream Inc., XpresSpa Holdings, LLC, XpresTest, Inc., and others. It operates in the Consumer Non-Cyclicals sector (SERVICES-PERSONAL SERVICES industry).

XWELL Inc is not a good buy right now due to its declining financial performance and negative market sentiment. The stock has a current price of $0.59, which is significantly lower than its 52-week high of $2.20, indicating a 73% drop from its peak. Additionally, the RSI is at 28.253, suggesting the stock is oversold, but this does not guarantee a rebound. The company reported a net loss of $22.4 million in Q2 2026, which raises concerns about its profitability. The stock has also seen a 14.72% drop over the last five days, reflecting ongoing negative sentiment.

Community

Mehr ↗

Noch keine Beiträge

Registriere dich oder melde dich an, um mitzudiskutieren

Ähnliche Artikel

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Jetzt handeln